High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A)

High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A) is an enzyme that specifically hydrolyzes cyclic guanosine monophosphate (cGMP), a key second messenger in various physiological processes. Unlike many other phosphodiesterases, PDE9A has the highest affinity for cGMP and does not significantly act on cAMP. It is widely expressed in the human body, with high concentrations found in the brain (particularly the hippocampus and cortex), hematopoietic cells, and the heart. In the central nervous system, PDE9A regulates synaptic plasticity and memory consolidation, making it a significant target for treating neurodegenerative disorders like Alzheimer's disease and Schizophrenia. In the context of hematology, PDE9A inhibition has been shown to increase fetal hemoglobin levels, providing a therapeutic avenue for sickle cell disease. Pharmacological targeting of PDE9A aims to elevate cGMP levels to restore signaling balance in diseased states, though clinical trials have faced challenges regarding efficacy in cognitive endpoints.

Other names

Phosphodiesterase 9APDE9HSPDE9A1cGMP-specific 3',5'-cyclic phosphodiesterase 9A

Selective inhibition of PDE9A prevents the hydrolysis of cyclic guanosine monophosphate (cGMP), thereby increasing intracellular cGMP concentrations and enhancing downstream signaling pathways such as the NO/sGC/cGMP pathway.